Videos
Can HCV Drug Regimens by Shortened Without Losing Efficacy?
Janice Wahl, MD, executive director of Infectious Diseases at Merck Research Laboratories, discusses how hepatitis C drugs have evolved and if a shorter treatment regimen is a viable option.
Sovaldi Inventor Sounds Off on High Drug Cost Controversy
Michael Sofia, PhD, the inventor of the groundbreaking hepatitis C drug sofosbuvir (Sovaldi), discusses the issues of high drug pricing and the cost of innovation.
Hepatitis C Patient Journey: The Impact on Quality of Life
In part six, Jim Wilson, RPh, MBA, president of WilsonRx, discusses how hepatitis C impacts the entire body.
The Characteristics of Merck's Promising New Hepatitis C Drug
Janice Wahl, MD, executive director of Infectious Diseases at Merck Research Laboratories, discusses the benefits of the grazoprevir/elbasvir HCV drug combination.
$auto_registration$